Gilead Sciences, Leerink

Gilead upgraded to outperform by Leerink on PreEP outlook
Leerink has upgraded Gilead Sciences (NASDAQ:GILD) to outperform, citing the growth outlook for its PrEP treatment lenacapavir for the prevention of HIV infection. The investment firm said that “any success” with data readouts for Gilead's (GILD) longer-acting HIV drugs “has an outsize impact on GILD’s” valuation,
Gilead Sciences, Inc. (GILD) Stock Rated Outperform by Leerink Partners
On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $88.16 which represents a slight increase of $1.87 or 2.17% from the prior close of $86.29. The stock opened at $85.
Gilead Sciences (NASDAQ:GILD) Upgraded to “Strong-Buy” at Leerink Partnrs
Leerink Partnrs upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Monday, Zacks.com reports. A number of other analysts also recently commented on GILD.
Gilead upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following
Leerink Partners Upgrades Gilead Sciences (GILD)
Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Market Perform to Outperform. Analyst Price Forecast Suggests 3.16% Downside As of September 24,
Gilead upgraded to outperform by Leerink on PrEP outlook
Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for the prevention of HIV infection. Read more here.
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Signaturefd LLC
Signaturefd LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.1% in the third ...
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...
Barchart on MSN1d
Gilead Sciences’ Quarterly Earnings Preview: What You Need to Know
Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its ...
Balanced Outlook on Gilead Sciences Amid Anticipated Anito-cel Trial Results
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...
FierceBiotech2d
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks, setting stage for pivotal program
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
FiercePharma7d
With Gilead coming fast, GSK bolsters case for long-acting HIV PrEP drug Apretude
With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...
Morgan Stanley says anito-cel Phase 2 data next catalyst for Gilead, Arcellx
Morgan Stanley notes that Gilead (GILD) and Arcellx’s (ACLX) anito-cel, a BCMA-directed CAR-T therapy in development for relapsed / ...
Business Wire3d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
FiercePharma5d
Gilead pulls Trodelvy's approval in bladder cancer after trial flop, FDA discussions
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
Yahoo Finance1d
Gilead and MSD to advance once-weekly HIV treatment to Phase III
Gilead Sciences and MSD are advancing their once-weekly HIV treatment regimen to Phase II trials, following promising ...